AVROBIO Stock Forecast, Price & News

-0.47 (-4.87 %)
(As of 06/18/2021 11:32 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume3,405 shs
Average Volume566,038 shs
Market Capitalization$383.41 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AVRO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVROBIO and its competitors with MarketBeat's FREE daily newsletter.



AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's lead product candidate is AVR-RD-01, a gene therapy which is in ongoing company-sponsored Phase 2 clinical trial and investigator-sponsored Phase 1 clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in Phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; AVR-RD-04 that is in investigator-sponsored Phase 1/2 clinical trial to treat cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage to treat Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.88 out of 5 stars

Medical Sector

140th out of 2,100 stocks

Biological Products, Except Diagnostic Industry

23rd out of 198 stocks

Analyst Opinion: 4.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

AVROBIO (NASDAQ:AVRO) Frequently Asked Questions

Is AVROBIO a buy right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AVROBIO in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVROBIO stock.
View analyst ratings for AVROBIO
or view top-rated stocks.

What stocks does MarketBeat like better than AVROBIO?

Wall Street analysts have given AVROBIO a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but AVROBIO wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is AVROBIO's next earnings date?

AVROBIO is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for AVROBIO

How were AVROBIO's earnings last quarter?

AVROBIO, Inc. (NASDAQ:AVRO) released its quarterly earnings data on Wednesday, May, 12th. The company reported ($0.65) EPS for the quarter, beating the consensus estimate of ($0.77) by $0.12.
View AVROBIO's earnings history

How has AVROBIO's stock price been impacted by COVID-19 (Coronavirus)?

AVROBIO's stock was trading at $18.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AVRO shares have decreased by 48.8% and is now trading at $9.22.
View which stocks have been most impacted by COVID-19

What price target have analysts set for AVRO?

10 equities research analysts have issued twelve-month price objectives for AVROBIO's shares. Their forecasts range from $10.00 to $36.00. On average, they expect AVROBIO's share price to reach $25.60 in the next year. This suggests a possible upside of 177.7% from the stock's current price.
View analysts' price targets for AVROBIO
or view top-rated stocks among Wall Street analysts.

Who are AVROBIO's key executives?

AVROBIO's management team includes the following people:
  • Mr. Geoff MacKay, Co- Founder, Pres, CEO & Director (Age 55, Pay $811.23k)
  • Mr. Erik Ostrowski M.B.A., CFO & Treasurer (Age 48, Pay $597.08k)
  • Mr. Steven N. Avruch J.D., Chief Legal Officer & Sec. (Age 60, Pay $506.68k)
  • Mr. Jeffrey Medin Ph.D., Scientific Founder
  • Mr. Matthew Arnold, Head of Operations
  • Mr. Kim Raineri M.B.A., Chief Manufacturing & Technology Officer
  • Dr. Christopher Mason FMEDSCI, M.D., Ph.D., FRCS, Chief Scientific Officer (Age 63)
  • Ms. Monique Da Silva, Sr. VP of Corp. Communications
  • Ms. Georgette Verdin, Chief HR Officer
  • Ms. Deanna M. Petersen MBA, Chief Bus. Officer (Age 59)

Who are some of AVROBIO's key competitors?

What other stocks do shareholders of AVROBIO own?


(AVRO) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities served as the underwriters for the IPO and Wedbush Securities was co-manager.

What is AVROBIO's stock symbol?

AVROBIO trades on the NASDAQ under the ticker symbol "AVRO."

Who are AVROBIO's major shareholders?

AVROBIO's stock is owned by many different institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (11.81%), BlackRock Inc. (8.35%), Federated Hermes Inc. (5.46%), Emerald Mutual Fund Advisers Trust (2.27%), Emerald Advisers LLC (2.20%) and Bank of New York Mellon Corp (2.05%). Company insiders that own AVROBIO stock include Bruce Booth, Christopher Paige and Geoffrey Mackay.
View institutional ownership trends for AVROBIO

Which institutional investors are selling AVROBIO stock?

AVRO stock was sold by a variety of institutional investors in the last quarter, including SV Health Investors LLC, Millennium Management LLC, Goldman Sachs Group Inc., Emerald Advisers LLC, Kennedy Capital Management Inc., Credit Suisse AG, Ameriprise Financial Inc., and Nuveen Asset Management LLC.
View insider buying and selling activity for AVROBIO
or view top insider-selling stocks.

Which institutional investors are buying AVROBIO stock?

AVRO stock was acquired by a variety of institutional investors in the last quarter, including Federated Hermes Inc., JPMorgan Chase & Co., Point72 Asset Management L.P., BlackRock Inc., Janus Henderson Group PLC, Morgan Stanley, DekaBank Deutsche Girozentrale, and Citigroup Inc..
View insider buying and selling activity for AVROBIO
or or view top insider-buying stocks.

How do I buy shares of AVROBIO?

Shares of AVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AVROBIO's stock price today?

One share of AVRO stock can currently be purchased for approximately $9.22.

How much money does AVROBIO make?

AVROBIO has a market capitalization of $385.08 million. The company earns $-119,710,000.00 in net income (profit) each year or ($3.31) on an earnings per share basis.

How many employees does AVROBIO have?

AVROBIO employs 121 workers across the globe.

What is AVROBIO's official website?

The official website for AVROBIO is

Where are AVROBIO's headquarters?


How can I contact AVROBIO?

AVROBIO's mailing address is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-914-8420 or via email at [email protected]

This page was last updated on 6/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.